| Title: |
Chronic activation of tubulin tyrosination improves heart function |
| Authors: |
Pietsch, Niels; Chen, Christina Y.; Kupsch, Svenja; Bacmeister, Lucas; Geertz, Birgit; Herrera-Rivero, Marisol; Siebels, Bente; Voß, Hanna; Krämer, Elisabeth; Braren, Ingke; Westermann, D.; Schlüter, Hartmut; Mearini, Giulia; Schlossarek, Saskia; Velden, Jolanda van der; Caporizzo, Matthew; Lindner, Diana; Prosser, Benjamin L.; Carrier, Lucie |
| Source: |
Circulation research. - 135, 9 (2024) , 910-932, ISSN: 1524-4571 |
| Publication Year: |
2024 |
| Collection: |
University of Freiburg: FreiDok |
| Description: |
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common cardiac genetic disorder caused by sarcomeric gene variants and associated with left ventricular hypertrophy and diastolic dysfunction. The role of the microtubule network has recently gained interest with the findings that microtubule detyrosination (dTyr-MT) is markedly elevated in heart failure. Acute reduction of dTyr-MT by inhibition of the detyrosinase (VASH [vasohibin]/SVBP [small VASH-binding protein] complex) or activation of the tyrosinase (TTL [tubulin tyrosine ligase]) markedly improved contractility and reduced stiffness in human failing cardiomyocytes and thus posed a new perspective for HCM treatment. In this study, we tested the impact of chronic tubulin tyrosination in an HCM mouse model (Mybpc3 knock-in), in human HCM cardiomyocytes, and in SVBP-deficient human engineered heart tissues (EHTs). METHODS: Adeno-associated virus serotype 9–mediated TTL transfer was applied in neonatal wild-type rodents, in 3-week-old knock-in mice, and in HCM human induced pluripotent stem cell–derived cardiomyocytes. RESULTS: We show (1) TTL for 6 weeks dose dependently reduced dTyr-MT and improved contractility without affecting cytosolic calcium transients in wild-type cardiomyocytes; (2) TTL for 12 weeks reduced the abundance of dTyr-MT in the myocardium, improved diastolic filling, compliance, cardiac output, and stroke volume in knock-in mice; (3) TTL for 10 days normalized cell area in HCM human induced pluripotent stem cell–derived cardiomyocytes; (4) TTL overexpression activated transcription of tubulins and other cytoskeleton components but did not significantly impact the proteome in knock-in mice; (5) SVBP-deficient EHTs exhibited reduced dTyr-MT levels, higher force, and faster relaxation than TTL-deficient and wild-type EHTs. RNA sequencing and mass spectrometry analysis revealed distinct enrichment of cardiomyocyte components and pathways in SVBP-deficient versus TTL-deficient EHTs. CONCLUSIONS: This study provides the first proof of ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
pdf |
| Language: |
English |
| Relation: |
https://freidok.uni-freiburg.de/data/257118 |
| DOI: |
10.1161/circresaha.124.324387 |
| Availability: |
https://freidok.uni-freiburg.de/data/257118; https://nbn-resolving.org/urn:nbn:de:bsz:25-freidok-2571183; https://doi.org/10.1161/circresaha.124.324387; https://freidok.uni-freiburg.de/dnb/download/257118 |
| Rights: |
free |
| Accession Number: |
edsbas.ACEA326A |
| Database: |
BASE |